137 related articles for article (PubMed ID: 7165996)
1. Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis.
ten Berge RJ; van Walbeek HK; Schellekens PT
Clin Exp Immunol; 1982 Dec; 50(3):495-502. PubMed ID: 7165996
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide.
Berd D; Maguire HC; Mastrangelo MJ
Cancer Res; 1984 Nov; 44(11):5439-43. PubMed ID: 6488195
[TBL] [Abstract][Full Text] [Related]
3. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.
Hermans G; Denzer U; Lohse A; Raus J; Stinissen P
J Autoimmun; 1999 Sep; 13(2):233-46. PubMed ID: 10479392
[TBL] [Abstract][Full Text] [Related]
4. Effects of cyclophosphamide on the lymphoid tissues and humoral and cellular immune responsiveness of young calves.
Corrier DE; Adams LG; Pierce KR
Am J Vet Res; 1979 Dec; 40(12):1683-9. PubMed ID: 118689
[TBL] [Abstract][Full Text] [Related]
5. Suppression of human B lymphocyte function by cyclophosphamide.
Cupps TR; Edgar LC; Fauci AS
J Immunol; 1982 Jun; 128(6):2453-7. PubMed ID: 6978904
[TBL] [Abstract][Full Text] [Related]
6. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
[TBL] [Abstract][Full Text] [Related]
7. Influence of azathioprine (imuran) on in vitro immune function in multiple sclerosis.
Oger JJ; Antel JP; Kuo HH; Arnason BG
Ann Neurol; 1982 Feb; 11(2):177-81. PubMed ID: 6462102
[TBL] [Abstract][Full Text] [Related]
8. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
[TBL] [Abstract][Full Text] [Related]
9. A 'profile' of immune responsiveness in multiple sclerosis.
Symington GR; Mackay IR; Whittingham S; White J; Buckley JD
Clin Exp Immunol; 1978 Feb; 31(2):141-9. PubMed ID: 306322
[TBL] [Abstract][Full Text] [Related]
10. Cell number requirements for lymphocyte stimulation in vitro: changes during the course of multiple sclerosis and the effects of immunosuppression.
Knight SC; Harding B; Burman S; Mertin J
Clin Exp Immunol; 1981 Oct; 46(1):61-9. PubMed ID: 7039882
[TBL] [Abstract][Full Text] [Related]
11. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
[TBL] [Abstract][Full Text] [Related]
12. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
Dawson DM; Carter JL; Hafler DA; Weiner HL
Riv Neurol; 1987; 57(2):88-91. PubMed ID: 3039645
[TBL] [Abstract][Full Text] [Related]
14. High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Gladstone DE; Golightly MG; Brannagan TH
J Neuroimmunol; 2007 Oct; 190(1-2):121-6. PubMed ID: 17854912
[TBL] [Abstract][Full Text] [Related]
15. Effects of immunosuppressive agents and particularly of cyclophosphamide on lymphocytes subsets in treated multiple sclerosis patients.
Gonsette RE; Defalque A; Demonty L
Riv Neurol; 1987; 57(3):181-4. PubMed ID: 2960008
[TBL] [Abstract][Full Text] [Related]
16. Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation.
Markewitz A; Faist E; Lang S; Endres S; Fuchs D; Reichart B
J Thorac Cardiovasc Surg; 1993 Jan; 105(1):15-24. PubMed ID: 8419695
[TBL] [Abstract][Full Text] [Related]
17. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
18. Immune surveillance in multiple sclerosis patients treated with natalizumab.
Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
[TBL] [Abstract][Full Text] [Related]
19. [Indices of cellular and humoral immunity in patients with disseminated sclerosis being treated with immunomodulators].
Zapadniuk BV; Kravets AS; Iarosh AA; Shurinok LA
Vrach Delo; 1988 Aug; (8):84-6. PubMed ID: 3206892
[No Abstract] [Full Text] [Related]
20. Immunosuppressive effects of cyclophosphamide, vincristine, and L-asparaginase in dogs.
Medleau L; Dawe DL; Calvert CA
Am J Vet Res; 1983 Feb; 44(2):176-80. PubMed ID: 6830007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
